19:59:47 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-18 Bokslutskommuniké 2024
2024-11-19 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-06-07 Ordinarie utdelning CALMA B 0.00 SEK
2024-06-05 Årsstämma 2024
2024-05-21 Kvartalsrapport 2024-Q1
2024-02-20 Bokslutskommuniké 2023
2023-12-14 Extra Bolagsstämma 2023
2023-11-21 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-23 Kvartalsrapport 2023-Q1
2023-05-17 Ordinarie utdelning CALMA B 0.00 SEK
2023-05-16 Årsstämma 2023
2023-02-21 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-09-22 Extra Bolagsstämma 2022
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-19 Ordinarie utdelning CALMA B 0.00 SEK
2022-05-17 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2022-02-23 Bokslutskommuniké 2021
2021-10-29 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-19 Ordinarie utdelning CALMA B 0.00 SEK
2021-05-18 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-12-23 Extra Bolagsstämma 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-20 Kvartalsrapport 2020-Q1
2020-05-15 Ordinarie utdelning CALMA B 0.00 SEK
2020-05-14 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-11-06 Extra Bolagsstämma 2019
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning CALMA B 0.00 SEK
2019-05-09 Årsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2018-11-26 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Calmark Sweden är verksamt inom medicinteknik. Bolaget specialiserar sig inom utveckling av diagnostiska verktyg riktade mot nyfödda barn. Tekniken utgår ifrån den egenutvecklade plattformen och används för analys de första veckorna efter födseln. Instrumentet används som biomarkör för att studera blodvärden. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget grundades under 2007 och har sitt huvudkontor i Karlstad.
2022-11-18 08:00:00

Calmark Sweden AB (publ) will participate in a delegation trip to India on November 28 - December 2 organized by Swecare, in collaboration with the Ministry of Health and Social Affairs, the Embassy of Sweden New Delhi, the Consulate General in Mumbai and Business Sweden. In connection with the delegation, a promotion tour will be made in the country together with the company's distributor r2 Diagnostics.

Swecare is a foundation that was established in 1978 and whose mission is to contribute to increased exports of Swedish products, services and knowledge in the life science area. International delegation trips are part of Swecare's core business.

Head of this delegation is Mr. Niclas Jacobson, Deputy Director General at the Ministry of Health and Social Affairs. Participating from Calmark will be Magdalena Tharaldsen, Director International Business Development. High-level representatives from government agencies, healthcare and academia as well as life science companies will also join.

The delegation will start in Mumbai, with meetings with the State Ministry of Health, visits to premium healthcare facilities and to network with local stakeholders in a reception at the Consulate General. The trip then continues to Jodhpur, where Sweden has a close partner in All India Institute for Medical Sciences (AIIMS). Center of Excellence in Cancer Control will be presented, as well as the Innovation Center and the Swedish contributions. Future areas of collaboration will be explored. The last day will be spent in New Delhi with study visits to public and private healthcare providers, an informative meeting on Modicare and discussions on procurement and how Swedish solutions best can contribute to Indian healthcare.

"I am very much looking forward to this trip as India is an important market for us. It feels fantastic to have the opportunity to travel together with r2 Diagnostics and present how our Neo products can make a difference in India," says Magdalena Tharaldsen, Director International Business Development for Calmark. "During the trip, I will also pay a visit to the MAMTA Health Institute for Mother and Child. Connecting with important key people in neonatal care will give us many advantages now that our products soon are in the commercialization phase."

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.